Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. - Wikidata - awgldk - TriplyDB

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

http://www.wikidata.org/entity/Q33349703

about

Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation HDAC inhibitors and immunotherapy; a double edged sword?BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.CDA: combinatorial drug discovery using transcriptional response modules The inverse F-BAR domain protein srGAP2 acts through srGAP3 to modulate neuronal differentiation and neurite outgrowth of mouse neuroblastoma cells Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays Use of big data in drug development for precision medicine.Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.A gene expression-based screening system for compounds influencing differentiation of mouse embryonic stem cells.k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction.DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome Functional dissection of HOXD cluster genes in regulation of neuroblastoma cell proliferation and differentiation.Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells.Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.DeltaNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation Cancer stem cells as a target population for drug discovery.Retinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro.Nonhistone protein acetylation as cancer therapy targets.Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context.Effect of low doses of actinomycin D on neuroblastoma cell lines Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.Genomic approaches to small molecule discovery.Retinoids regulate stem cell differentiation Integrative genomics strategies to elucidate the complexity of drug response.Immunocombination therapy for high-risk neuroblastoma.Epigenetic drugs for cancer treatment and prevention: mechanisms of action.Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.Achaete-Scute Homolog 1 Expression Controls Cellular Differentiation of Neuroblastoma.Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells.HOXC9 links cell-cycle exit and neuronal differentiation and is a prognostic marker in neuroblastoma New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiation Combination therapies improve the anticancer activities of retinoids in neuroblastoma.Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming.

P2860

Q24635235-0C0D794C-4F18-4CD4-BA85-3D33CF537833 Q26853102-42F70772-1C53-4A07-9689-A4F788B1B71D Q27851610-C502BE48-8B8A-40C4-9619-C8DA300B1E6A Q28482122-B259857B-4C90-4D80-A693-B82F22F5C8CA Q28487781-4304A84B-F190-4FD4-8810-08263455F48E Q28550025-F81597D9-3E38-4188-BC73-5AD45117E04B Q31115480-2C5B9727-693A-40D1-B22F-6EBCBC07AAB0 Q33808326-3B9B77DC-BBDF-47D0-9390-4B9A7623944B Q34037409-69AA2232-5EE7-4307-B7A0-F1F1FE7AF70F Q34059963-DAB08291-C629-4995-8B96-32ACCE575014 Q34111103-52A31F14-CE5C-49C4-B632-F5D6F5E7185F Q34247959-5D13A862-DE6D-4080-AFEE-65D44CCB6455 Q34373947-A18E4198-C0EB-4E64-BA84-C32311146748 Q34480664-E824C6D5-46E7-494D-9CB9-95C7668B4C43 Q34739990-4A354D56-DB32-4FA2-B1EB-6FA50781C134 Q34752036-9DB92039-E69D-4F02-88B5-A864B8B3F9E1 Q35390334-C7AB4FAD-5D1C-4F0A-AFB7-B9C7F941A5FC Q35617537-074B9C7D-3E89-4803-AABA-AD7E8F88C091 Q35739676-626104F1-21AB-4E40-8AB5-8FABA2907BAA Q36086869-93080897-BB19-4B85-BA48-EA86F9BE1B11 Q36423770-D7C35A62-DF2D-4470-8825-CE8CFFD6A67F Q37007949-3AAD85A2-5F0D-4D63-9CC9-82CF7E6A65E7 Q37078946-E1C82C1E-9389-4B7D-965C-E07DD5197C73 Q37259264-8C86A2AC-C94B-4343-9225-A2245ED7CC76 Q37325233-F82DD3A5-E29F-40D7-A479-CEF56DF2C48D Q37406963-85A1F100-CF56-4585-9818-B4EEC6EAC7D6 Q37788067-0CC3B048-5F66-4E5B-9438-5D4A461EFCCB Q37961088-5B768CA9-F865-4B7F-9345-FECCFCD7CF7F Q37991024-1AB29147-02F9-4271-9DBE-829E13905CBA Q38472433-396AF5C8-BE03-4686-99C7-E6284105FF35 Q38716908-43D648DE-5F2D-4EFD-81B3-22CC6704B142 Q38973422-A58F202B-4721-4E0A-9A76-1B84C7A8B2B2 Q39032925-1416E9E2-F386-4C29-8DA8-3D7862BD8F08 Q39475732-0C7D1D44-56B2-4119-9416-00BA2E9F28B0 Q39555632-CAF582E0-502B-475E-8FBC-25CA89C3E96B Q39639490-CFB00086-ED24-4398-A11E-9EDB43CAA7EC Q42276835-1F9DA37E-B994-40F1-8AE0-D7C256FCF444 Q42670722-3993EA60-C0D2-45F6-A705-DBD3B1ADA74C Q43134812-EF6D8D3E-E80A-44A7-BCD4-D4FFA5E425B6 Q49068138-3F9AEB78-4EE4-423E-80E2-AE2CB5272AF7

P2860

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

http://www.wikidata.org/entity/Q33349703

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Expression-based screening ide ...... neuroblastoma differentiation.

@ast

Expression-based screening ide ...... neuroblastoma differentiation.

@en

type

label

Expression-based screening ide ...... neuroblastoma differentiation.

@ast

Expression-based screening ide ...... neuroblastoma differentiation.

@en

prefLabel

Expression-based screening ide ...... neuroblastoma differentiation.

@ast

Expression-based screening ide ...... neuroblastoma differentiation.

@en

P1433

Q33349703-F1AE4767-EFC2-4A46-88F7-ABB9E33034A9

P1476

Q33349703-3184451E-0319-4E4C-A9B6-B489C036E3AE

P2093

Q33349703-198BFEB8-A4FA-435D-BDB4-DC5DAF92CB07

Q33349703-1D778FF6-11FD-49B1-A966-4AFAF2BCA13B

Q33349703-2E863096-1E69-4CEB-A47E-1C4E7B9A5AB4

Q33349703-869037E3-1073-4A75-8A3F-1265737456FF

Q33349703-94263E46-C484-4304-B743-4E361D935690

Q33349703-B4AF73C2-1B11-4006-8381-588C65C19902

Q33349703-D52597D7-157C-43FB-9572-FF0E506A3596

P2860

Q33349703-062C582D-146A-441E-87F4-B685984C71D3

Q33349703-06AE8843-8DE8-4F9A-8A7F-E7F3E0606A52

Q33349703-23F367CF-16CB-4A77-AD97-DDD3A9720C84

Q33349703-310F5425-9DBC-4D43-BCA0-D883B272404D

Q33349703-394BB6E2-418A-4B24-906B-9FBD949D6887

Q33349703-39FCFA9B-6AC4-4933-8C14-6DE286FC6B5B

Q33349703-3A528D7D-ADA6-4568-9D48-2D98DEFF95FD

Q33349703-3A82543F-042D-4C0A-8FEB-3B4489A65DF6

Q33349703-3E6DB713-6317-4F7B-802F-B60D68F8B246

Q33349703-53341F4F-FB37-4F79-933D-5E3D9BDA53FA

P304

Q33349703-6E3B0598-6232-466A-8E1F-F12F6434E096

P31

Q33349703-524F3E15-E9C0-46C8-94A2-04609875598E

P356

Q33349703-356DBF16-39AF-43C3-9906-96C473E363B1

P407

Q33349703-F5EC6F92-E6C3-46C2-BB2C-F03CF7FB9F0B

P433

Q33349703-A846E202-4EBE-412D-A939-CA2F2242FF22

P478

Q33349703-F6F596D6-F3F1-4E36-8ABC-35FA17A37347

P50

Q33349703-90B6713F-098F-44CB-9052-8E2C3101D092

Q33349703-C44B686E-A061-4068-8496-94A0E32684B2

P577

Q33349703-E7D98773-4513-44A0-AD52-F9E389C03383

P5875

Q33349703-155ABECD-3DF3-4F7E-9DBE-AB50C4CF0991

P698

Q33349703-2795C281-0B80-4B72-BA73-427D79582CD3

P932

Q33349703-D55B353A-6583-423E-9467-AB726E08D8D4

P356

PNAS.0710413105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Expression-based screening ide ...... neuroblastoma differentiation.

@en

P2093

Cindy M Kanegai

http://www.w3.org/2001/XMLSchema#string

Cynthia K Hahn

http://www.w3.org/2001/XMLSchema#string

Ian M Warrington

http://www.w3.org/2001/XMLSchema#string

Kenneth N Ross

http://www.w3.org/2001/XMLSchema#string

Ralph Mazitschek

http://www.w3.org/2001/XMLSchema#string

Renee D Wright

http://www.w3.org/2001/XMLSchema#string

Todd R Golub

http://www.w3.org/2001/XMLSchema#string

P2860

ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors

Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Role of the histone deacetylase complex in acute promyelocytic leukaemia

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase

Anticancer activities of histone deacetylase inhibitors

Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Mechanisms of action of valproate: a commentatory.

P304

9751-9756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0710413105

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Kimberly Stegmaier

P577

2008-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5246028

http://www.w3.org/2001/XMLSchema#string

P698

18607002

http://www.w3.org/2001/XMLSchema#string

P932

2474517

http://www.w3.org/2001/XMLSchema#string